CVAC vs ARCT vs MRNA vs BNTX

For growth investors, CureVac N.

V. (CVAC) is the stronger pick with 895. 5% revenue growth year-over-year, versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). CureVac N. V. (CVAC) offers the better valuation at 6. 5x trailing P/E, making it the more compelling value choice. Analysts rate Arcturus Therapeutics Holdings Inc. (ARCT) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BioNTech SE (BNTX) delivered a total return of -48.

2%, compared to -95. 4% for CureVac N. V. (CVAC). Over 10 years, the gap is even starker: BNTX returned +568. 1% versus CVAC's -91. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioNTech SE (BNTX) is the lower-risk stock at 1.

14β versus Arcturus Therapeutics Holdings Inc. 's 2. 41β — meaning ARCT is approximately 111% more volatile than BNTX relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 22% for Moderna, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CureVac N.

V. (CVAC) is pulling ahead at 895. 5% versus -51. 4% for Arcturus Therapeutics Holdings Inc. (ARCT). On earnings-per-share growth, the picture is similar: CureVac N. V. grew EPS 161. 0% year-over-year, compared to -62. 8% for BioNTech SE. Over a 3-year CAGR, CVAC leads at 73. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CureVac N.

V. (CVAC) is the more profitable company, earning 30. 3% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 30. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CVAC leads at 33. 2% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — ARCT leads at 95. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BioNTech SE (BNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

14), +568. 1% 10Y return). Arcturus Therapeutics Holdings Inc. (ARCT) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BNTX: +568. 1%, ARCT: -69. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CVAC is a small-cap high-growth stock; ARCT is a small-cap quality compounder stock; MRNA is a mid-cap quality compounder stock; BNTX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.